Published on 2 July 2007
Genmab regains lymphoma drug rights
teaser
It is normally a sign of bad news but Genmab says it is delighted that Merck KGaA has returned the rights to a new lymphoma drug to the Denmark-based drugmaker.
Genmab has regained all rights to the HuMax-CD4
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine